| |
|
|
|
Trillium Therapeutics Inc.  
|
|
2.72 0.03 (0.01%) |
11-20 14:43 |
|
Open: |
2.7 |
Pre close: |
2.69 |
Target:
|
3.88 
|
|
High: |
2.89 |
Low: |
2.431 |
Resistance:
|
3.32
3.96
|
|
Volume: |
14,227 |
Market Cap: |
39M |
Support:
|
2.28
1.90
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
2.74
 |
MACD |
MACD(12,26):
|
-0.38 |
|
MA(20): |
3.07 |
Signal(12,26,9): |
-0.41 |
|
MA(100): |
4.88 |
Stochastic Oscillator |
%K(14,3):
|
40.16 |
|
MA(250): |
6.35 |
%D(3): |
39.04 |
|
Average Volume(K) |
3-Month: |
12036
|
52-Week |
High:
|
13.30 |
|
10-Days: |
7764 |
Low: |
2.28 |
|
RSI |
RSI(14):
|
37.72 |
Change(%): |
-76.0 |
|
Financials, Statistics and Valuation |
|
EPS |
-2.640 |
Return on Equity (ttm) |
-643.6 |
Shares Out. (M) |
14.69 |
|
EPS Est. Current Year |
-4.130 |
Return on Assets (ttm) |
-63.5 |
Shares Float (M) |
14.69 |
|
EPS Est. Next Year |
-2.740 |
PEG Ratio |
0.00 |
% Held by Insiders |
0.00 |
|
EPS Est. Next Quarter |
-0.960 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
53.50 |
|
Forward EPS |
-2.917 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
0 |
|
Book Value (p.s.) |
32.580 |
EBITDA (p.s.) |
0.000 |
P/E |
-1.05 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
0.09 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-24.74 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-14.40 |
P/CF |
-1.65 |
|
|
|
|
|
|
